Suppr超能文献

在 HLA 配型相合的同胞供者移植中,对于患有严重获得性再生障碍性贫血的年轻患者,外周血祖细胞移植比骨髓移植的结局更差,慢性移植物抗宿主病更多。

Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia.

作者信息

Schrezenmeier Hubert, Passweg Jakob R, Marsh Judith C W, Bacigalupo Andrea, Bredeson Christopher N, Bullorsky Eduardo, Camitta Bruce M, Champlin Richard E, Gale Robert Peter, Fuhrer Monika, Klein John P, Locasciulli Anna, Oneto Rosi, Schattenberg Antonius V M B, Socie Gerard, Eapen Mary

机构信息

Institute of Clinical Transfusion Medicine and Immunogenetics, University of Ulm, Germany.

出版信息

Blood. 2007 Aug 15;110(4):1397-400. doi: 10.1182/blood-2007-03-081596. Epub 2007 May 2.

Abstract

We analyzed the outcome of 692 patients with severe aplastic anemia (SAA) receiving transplants from HLA-matched siblings. A total of 134 grafts were peripheral blood progenitor cell (PBPC) grafts, and 558 were bone marrow (BM) grafts. Rates of hematopoietic recovery and grades 2 to 4 chronic graft-versus-host disease (GVHD) were similar after PBPC and BM transplantations regardless of age at transplantation. In patients older than 20 years, chronic GVHD and overall mortality rates were similar after PBPC and BM transplantations. In patients younger than 20 years, rates of chronic GVHD (relative risk [RR] 2.82; P = .002) and overall mortality (RR 2.04; P = .024) were higher after transplantation of PBPCs than after transplantation of BM. In younger patients, the 5-year probabilities of overall survival were 73% and 85% after PBPC and BM transplantations, respectively. Corresponding probabilities for older patients were 52% and 64%. These data indicate that BM grafts are preferred to PBPC grafts in young patients undergoing HLA-matched sibling donor transplantation for SAA.

摘要

我们分析了692例接受人类白细胞抗原(HLA)匹配同胞供者移植的重型再生障碍性贫血(SAA)患者的预后情况。共有134例移植物为外周血祖细胞(PBPC)移植物,558例为骨髓(BM)移植物。无论移植时的年龄如何,PBPC移植和BM移植后的造血恢复率以及2至4级慢性移植物抗宿主病(GVHD)的发生率相似。在年龄大于20岁的患者中,PBPC移植和BM移植后的慢性GVHD和总死亡率相似。在年龄小于20岁的患者中,PBPC移植后的慢性GVHD发生率(相对危险度[RR] 2.82;P = 0.002)和总死亡率(RR 2.04;P = 0.024)高于BM移植后。在年轻患者中,PBPC移植和BM移植后的5年总生存率分别为73%和85%。老年患者的相应概率分别为52%和64%。这些数据表明,在接受HLA匹配同胞供者移植治疗SAA的年轻患者中,BM移植物优于PBPC移植物。

相似文献

引用本文的文献

1
Graft Source Choice.移植物来源的选择。
Adv Exp Med Biol. 2025;1475:57-75. doi: 10.1007/978-3-031-84988-6_4.
10
Cancer Immunotherapy Beyond Checkpoint Blockade: State-of-the-Art Review.超越检查点阻断的癌症免疫疗法:最新综述。
JACC CardioOncol. 2022 Dec 20;4(5):563-578. doi: 10.1016/j.jaccao.2022.11.006. eCollection 2022 Dec.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验